{
    "name": "silver sulfadiazine",
    "comment": "Rx",
    "other_names": [
        "Silvadene",
        "Thermazene",
        "SSD Cream"
    ],
    "classes": [
        "Antibacterials",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/silvadene-thermazene-silver-sulfadiazine-343477",
    "pregnancy": {
        "common": [
            "Pregnancy category: C, X (near term)",
            "Lactation: Not known if distributed into breast milk; use caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Not known if distributed into breast milk; use caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Sulfa allergy",
                "Hypersensitivity",
                "Pregnant women at term or near term; premature infants, or in infants 2 months or younger"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in G6PD deficiency; hemolysis may occur",
                "For topical use only; avoid contact with eyes",
                "Prolonged use may result in bacterial or fungal superinfection",
                "Not recommended for use in pregnant women unless the burned area covers more than 20% of body surface or therapeutic benefits to patient outweigh the possible risks to the fetus",
                "Although silver sulfadiazine is minimally absorbed, it reacts with body fluids to release sulfadiazine, which is absorbed and may reach substantial serum concentrations",
                "Absorption of silver sulfadiazine varies depending on the percent of body surface area and the extent of the tissue damage; it is possible that any adverse reaction associated with sulfonamides may occur including blood dyscrasias, dermatologic and allergic reactions (including life-threatening cutaneous reactions [Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), exfoliative dermatitis]), GI reactions, hepatitis and hepatocellular necrosis, CNS reactions, and toxic nephrosis",
                "Use caution in hepatic/renal impairment",
                "For topical use only; avoid contact with eye"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "allogeneic cultured keratinocytes and fibroblasts",
            "description": {
                "common": "silver sulfadiazine decreases effects of allogeneic cultured keratinocytes and fibroblasts by Other (see comment). Avoid or Use Alternate Drug. \nComment: Silver-containing antimicrobials and dressings may decrease viability of keratinocytes and human dermal fibroblasts. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "collagenase",
            "description": {
                "common": "silver sulfadiazine decreases effects of collagenase by Other (see comment). Use Caution/Monitor. \nComment: Heavy metal ions inactivate enzymes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "papain",
            "description": {
                "common": "silver sulfadiazine decreases effects of papain by Other (see comment). Use Caution/Monitor. \nComment: Heavy metal ions inactivate enzymes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trypsin",
            "description": {
                "common": "silver sulfadiazine decreases effects of trypsin by Other (see comment). Use Caution/Monitor. \nComment: Heavy metal ions inactivate enzymes."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "collagenase",
            "description": {
                "common": "collagenase decreases effects of silver sulfadiazine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "papain",
            "description": {
                "common": "papain decreases effects of silver sulfadiazine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trypsin",
            "description": {
                "common": "trypsin decreases effects of silver sulfadiazine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Pain",
            "percent": "6"
        },
        {
            "name": "Burning",
            "percent": null
        },
        {
            "name": "Itching",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Necrosis of the skin",
            "percent": null
        },
        {
            "name": "Erythema multiforme",
            "percent": null
        },
        {
            "name": "Transient skin discoloration",
            "percent": null
        },
        {
            "name": "Hemolytic anemia",
            "percent": null
        },
        {
            "name": "in patients with G",
            "percent": null
        },
        {
            "name": "PD deficiency",
            "percent": null
        },
        {
            "name": "Agranulocytosis",
            "percent": null
        },
        {
            "name": "Aplastic anemia",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        },
        {
            "name": "Leukopenia",
            "percent": null
        },
        {
            "name": "Dermatologic and hypersensitivity reactions",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        },
        {
            "name": "TEN",
            "percent": null
        },
        {
            "name": "Adverse GI effects",
            "percent": null
        },
        {
            "name": "Hepatitis and hepatocellular necrosis",
            "percent": null
        },
        {
            "name": "Adverse nervous system effects",
            "percent": null
        },
        {
            "name": "Toxic nephrosis",
            "percent": null
        },
        {
            "name": "Interstitial nephritis",
            "percent": null
        }
    ]
}